A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Status:
COMPLETED
Trial end date:
2025-08-25
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.